Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Glucocorticoids in 2015

New answers to old problems

Since glucocorticoids were first used to treat patients with rheumatoid arthritis in 1949, they have become the most common therapy for inflammatory disorders; however, their use is associated with major metabolic adverse events. Here, we review three 2015 reports with clinical and fundamental implications for the use of glucocorticoid therapy in rheumatology.

Your institute does not have access to this article

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Beneficial anti-inflammatory effects versus harmful metabolic consequences of glucocorticoids.


  1. Hillier, S. G. Diamonds are forever: the cortisone legacy. J. Endocrinol. 195, 1–6 (2007).

    CAS  Article  Google Scholar 

  2. Ruiz-Arruza, I. et al. Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus. Rheumatology (Oxford) 53, 1470–1476 (2014).

    CAS  Article  Google Scholar 

  3. Thamer, M., Hernan, M. A., Zhang, Y., Cotter, D. & Petri, M. Prednisone, lupus activity, and permanent organ damage. J. Rheumatol. 36, 560–564 (2009).

    CAS  Article  Google Scholar 

  4. Chen, S. Y. et al. Glucocorticoid use in patients with systemic lupus erythematosus: association between dose and health care utilization and costs. Arthritis Care Res. (Hoboken) 67, 1086–1094 (2015).

    CAS  Article  Google Scholar 

  5. Beaulieu, E. & Morand, E. F. Role of GILZ in immune regulation, glucocorticoid actions and rheumatoid arthritis. Nat. Rev. Rheumatol. 7, 340–348 (2011).

    CAS  Article  Google Scholar 

  6. Jones, S. A. et al. GILZ regulates TH17 responses and restrains IL-17-mediated skin inflammation. J. Autoimmun. 61, 73–80 (2015).

    CAS  Article  Google Scholar 

  7. Bruscoli, S. et al. Lack of glucocorticoid-induced leucine zipper (GILZ) deregulates B cell survival and results in B cell lymphocytosis in mice. Blood 126, 1790–1801 (2015).

    CAS  Article  Google Scholar 

  8. Jones, S. A. et al. Glucocorticoid-induced leucine zipper (GILZ) inhibits B cell activation in systemic lupus erythematosus. Ann. Rheum. Dis. (2015).

  9. Jones, S. A., Sutton, C. E., Cua, D. & Mills, K. H. Therapeutic potential of targeting IL-17. Nat. Immunol. 13, 1022–1025 (2012).

    CAS  Article  Google Scholar 

  10. Schewitz-Bowers, L. P. et al. Glucocorticoid-resistant TH17 cells are selectively attenuated by cyclosporine A. Proc. Natl Acad. Sci. USA 112, 4080–4085 (2015).

    CAS  Article  Google Scholar 

Download references


The authors wish to thank the Lupus Research Institute, the National Health and Medical Research Council of Australia and the Ulysses Club Arthritis Research Fund for funding their work.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Eric F. Morand.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Jones, S., Morand, E. New answers to old problems. Nat Rev Rheumatol 12, 73–74 (2016).

Download citation

  • Published:

  • Issue Date:

  • DOI:

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing